Compare drug alternatives

Ubrelvy® Alternatives

Ubrelvy®(ubrogepant)
Nurtec®(rimegepant)
Prescription Only
Ubrelvy is a medication that adults can use to treat acute migraine attacks. It works by blocking CGRP, a protein believed to contribute to migraine attacks by causing pain, blood...
Prescription Only
Nurtec ODT is a medication that can be placed under or onto the tongue to treat migraine symptoms in adults. When taken every other day, it can also be used to prevent episodic...
Dosage & Administration
Administration
Oral. Learn more.
Oral . Learn more.
Dosing
50 mg or 100 mg as needed. Maximum daily dose: 200 mg. Severe Hepatic or Severe Renal Impairment: 50 mg.. Learn more.
Acute treatment of migraine: 75 mg as needed. Preventive treatment of episodic migraine: 75 mg every other day. Maximum daily dose: 75 mg.. Learn more.
Latin Shorthand
50 mg PRN or 100 mg PRN. Severe Renal Impairment: 50mg.. Learn more.
Acute treatment of Migraine: 75 mg PRN. Preventive treatment of Episodic Migraine: 75 mg qod.. Learn more.
Financial Assistance
Out-Of-Pocket Costs With Copay Card
Annual Cap
Maximum savings of $50 per pill for up to 13 prescription fills.. Learn more.
Assistance Expiration
13 prescription fills. Learn more.
Generics
No lower-cost generic available
No lower-cost generic available
Physician Advisory
Adverse Reactions
The most common adverse reactions (at least 2% and greater than placebo) were nausea and somnolence.. Learn more.
Acute treatment of migraine: the adverse reaction reported in ≥ 1% of patients treated with NURTEC ODT is nausea. Preventive treatment of episodic migraine: adverse reactions reported in ≥ 2% for rimegepant and ≥ 1% higher than placebo are nausea and abdominal pain/dyspepsia.. Learn more.
Mechanism of Actions (MoA)
CGRP Antagonist. Learn more.
CGRP Antagonist. Learn more.
Special Populations
Is it safe to take UBRELVY during pregnancy?

There are no adequate data on the developmental risk associated with the use of UBRELVY in pregnant women. Patients should be encouraged to enroll in the pregnancy exposure registry that monitors outcomes in women who become pregnant while taking UBRELVY by calling 1-833-277-0206 or visiting http://empresspregnancyregistry.com.

What is the risk of birth defects or miscarriage when taking UBRELVY during pregnancy?

In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The estimated rate of major birth defects (2.2% -2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine. However, no adequate data on the developmental risk associated with the use of UBRELVY in pregnant women is available.

What are the clinical considerations when taking UBRELVY during pregnancy?

Published data have suggested that women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy.

What does animal data suggest about the use of UBRELVY during pregnancy?

In animal studies, adverse effects on embryofetal development were observed following administration of ubrogepant during pregnancy or during pregnancy and lactation at doses greater than those used clinically and which were associated with maternal toxicity. No adverse effects on embryofetal development were observed when ubrogepant was administered to pregnant rats during the period of organogenesis. However, no adequate data on the developmental risk associated with the use of UBRELVY in pregnant women is available.

What is the risk of taking UBRELVY while breastfeeding?

There are no data on the presence of ubrogepant in human milk, the effects of ubrogepant on the breastfed infant, or the effects of ubrogepant on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for UBRELVY and any potential adverse effects on the breastfed infant from UBRELVY or from the underlying maternal condition.

Is it safe to use UBRELVY in pediatric patients?

Safety and effectiveness in pediatric patients have not been established.

Are there any pharmacokinetic differences between elderly and younger patients when taking UBRELVY?

Pharmacokinetic studies have shown no clinically significant differences between elderly and younger patients when taking UBRELVY.

Was the use of UBRELVY studied in elderly patients?

Clinical studies of UBRELVY did not include enough elderly patients to determine if they respond differently from younger patients. Dose selection for elderly patients should be cautious and typically start at the low end of the dosing range.

How does hepatic impairment affect the exposure to UBRELVY?

In patients with mild, moderate, or severe hepatic impairment, exposure to UBRELVY was increased by 7%, 50%, and 115%, respectively. No dose adjustment is necessary for mild or moderate hepatic impairment. However, for patients with severe hepatic impairment, dose adjustment is recommended.

How does renal impairment affect the use of UBRELVY?

Renal impairment has a minor effect on the clearance of UBRELVY. No dose adjustment is needed for patients with mild or moderate renal impairment. For those with severe renal impairment (CLcr 15-29 mL/min), dose adjustment is necessary. Patients with end-stage renal disease (CLcr <15 mL/min) should avoid the use of UBRELVY.

Is NURTEC ODT safe to use during pregnancy?

There are no adequate data on the developmental risk associated with the use of NURTEC ODT in pregnant women. In animal studies, oral administration of rimegepant during organogenesis resulted in adverse effects on development in rats (decreased fetal body weight and increased incidence of skeletal variations) at exposures greater than those used clinically and which were associated with maternal toxicity. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. The estimated rate of major birth defects (2.2 to 2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine. Women exposed to NURTEC ODT during pregnancy can participate in a pregnancy exposure registry that monitors pregnancy outcomes. Healthcare providers or patients can contact 1-877-366-0324, email nurtecpregnancyregistry@ppd.com, or visit nurtecpregnancyregistry.com for more information.

Can I take NURTEC ODT while breastfeeding?

A lactation study conducted on 12 healthy adult lactating women who were between 2 weeks and 6 months postpartum and were administered a single oral dose of rimegepant 75 mg established a relative infant dose of less than 1% of the maternal weight-adjusted dose and a milk-to-plasma ratio of 0.20. These data support that transfer of rimegepant into breastmilk is low. However, there are no data on the effects of rimegepant on a breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for NURTEC ODT and any potential adverse effects on the breastfed infant from NURTEC ODT or from the underlying maternal condition.

Is NURTEC ODT safe for use in children?

Safety and effectiveness in pediatric patients have not been established for NURTEC ODT.

Is NURTEC ODT safe for use in elderly patients?

In pharmacokinetic studies, no clinically significant pharmacokinetic differences were observed between elderly and younger subjects. However, clinical studies of NURTEC ODT did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Do patients with renal impairment need a dosage adjustment of NURTEC ODT?

No, dosage adjustment is not required in patients with mild, moderate, or severe renal impairment. However, NURTEC ODT has not been studied in patients with end-stage renal disease and in patients on dialysis. It is advised to avoid the use of NURTEC ODT in patients with end-stage renal disease (CLcr < 15 mL/min).

What is the recommended dose of NURTEC ODT for patients with severe renal impairment?

The recommended dosage of NURTEC ODT for patients with severe renal impairment (CLcr 15-29 mL/min) is the same as for patients with normal renal function, which is a single dose of 75 mg. However, NURTEC ODT has not been studied in patients with end-stage renal disease and in patients on dialysis. It is advised to avoid the use of NURTEC ODT in patients with end-stage renal disease (CLcr < 15 mL/min).

Can patients on dialysis use NURTEC ODT?

NURTEC ODT has not been studied in patients on dialysis. It is advised to avoid the use of NURTEC ODT in patients with end-stage renal disease (CLcr < 15 mL/min).